Press release
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size
What Is the Current Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size and Its Estimated Growth Rate?
The market size for glucagon-like peptide (GLP)-1 agonists weight loss medications has seen impressive growth in recent times. Projected to expand from $13.38 billion in 2024 to $15.63 billion in 2025, the market will experience a compound annual growth rate (CAGR) of 16.9%. The expansion during the historic period can be ascribed to factors such as increasing obesity incidence, rising cases of type 2 diabetes, enhanced knowledge about health risks related to obesity, elevated healare spending, greater attention to managing chronic illnesses, and better access to healare services.
Anticipated to experience a swift rise in its expansion, the market size for glucagon-like peptide (GLP) -1 agonists weight loss drugs is projected to reach a value of $28.91 billion in 2029, escalating at a compound annual growth rate (CAGR) of 16.6%. Several factors contribute to this growth anticipated in the forecast period, including the escalating demand for potent weight loss methods, extension of drug indications beyond diabetes, heightened investments in research and development, adopting more personalized medications, and an increase in awareness due to direct-to-consumer marketing strategies. Key trends that are expected during the forecast timeframe include the creation of oral glucagon-like peptide (GLP)-1 formulations, advances in sustained-release medication delivery, the inclusion of digital health technologies for monitoring, implementation of artificial intelligence in discovering and developing drugs, and innovations in peptide engineering to enhance efficacy.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
How Are Emerging Segments Shaping the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Landscape?
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market covered in this report is segmented -
1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic, Wegovy, Rybelsus
2) By Liraglutide: Saxenda, Victoza
3) By Tirzepatide: Mounjaro, Zepbound
4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
Which Growth Factors Are Influencing Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Expansion?
An increase in obesity rates is anticipated to fuel the upward trajectory of the GLP-1 agonist weight loss drug market. This medical condition, known as obesity, is typified by an unhealthy accumulation of body fat that poses a risk to wellbeing. Unhealthy diets, typified by excessive consumption of fast food and sugary beverages, lacking nutritional balance, leads to increasing obesity rates. As the number of people affected by obesity-related health complications increase, the demand for effective treatments escalates, boosting the use of GLP-1 agonist weight loss drugs because of their demonstrated ability to promote weight loss and improve metabolic health. For example, the World Health Organization, a Switzerland-based intergovernmental organization, reported in March 2024 that, in 2022, every eighth person worldwide was obese. Out of the 2.5 billion adults who were overweight, roughly 890 million were classified as obese. Moreover, it was found that about 43% of the global adult population was overweight, with 16% categorized as obese. Hence, the escalating rates of obesity are driving growth in the GLP-1 agonist weight loss drug market.
Who Are the Dominant Players Across Different Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segments?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.
What Trends Are Driving Growth in The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Key players in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are advancing groundbreaking obesity treatments to raise efficacy and boost patient results. These treatments involve therapies that simulate the GLP-1 hormone to control hunger, increase the feeling of fullness, and facilitate weight loss. These medications aid in managing obesity by enhancing metabolic activity and endorsing sustainable weight control. For example, in November 2023, US pharmaceutical firm, Eli Lilly and Company, received approval from the US Food and Drug Administration for Zepbound, a chronic weight management drug for adults suffering from obesity or overweight along with associated ailments like type 2 diabetes or sleep apnea. The drug functions by triggering GIP and GLP-1 hormone receptors to curb hunger and amplify metabolic activity.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-glp-1-agonists-weight-loss-drugs-global-market-report
Which Geographic Regions Are Expected to Dominate the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market in the Coming Years?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
2. What is the CAGR expected in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
3. What Are the Key Innovations Transforming the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?
4. Which Region Is Leading the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis here
News-ID: 4060759 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for GLP
Alpharetta Medical Clinic Earns Top Recognition for Excellence in Peptide, GLP-1 …
Dr. Weight Loss of Atlanta in Alpharetta is proud to announce its recognition as the top-rated provider of medical weight loss and peptide therapy services in the Alpharetta area. This distinction reflects the clinic's sustained commitment to clinical excellence, patient-centered care, and successful treatment outcomes in the field of metabolic health.
Alpharetta, GA - December 16, 2025 - Dr. Weight Loss of Atlanta [https://drweightlossofatlanta.com/peptide-therapy-alpharetta] in Alpharetta is proud to announce its…
Medical Clinic Recognized as Top Peptide, GLP-1, & GLP-3 Therapies in Sandy Spri …
Dr. Weight Loss of Atlanta announced today that its Sandy Springs location has earned recognition as a leading medical weight loss and peptide therapy clinic in Sandy Springs, reflecting exceptional patient satisfaction, consistently strong clinical outcomes, and a reputation for delivering personalized, expert-guided care.
Sandy Springs, GA - December 16, 2025 - Dr. Weight Loss of Atlanta [https://drweightlossofatlanta.com/peptides-sandy-springs] announced today that its Sandy Springs location has earned recognition as a leading…
My Start GLP 1 Reviews: The GLP 1 That is Changing the Way America loss Weight
In the modern era of health innovation, few breakthroughs have generated as much excitement as My Start GLP 1. In 2025, it has rapidly become one of the most talked-about doctor-supervised weight loss programs in the United States. With thousands of verified patient success stories, My Start GLP 1 has positioned itself as more than a trend-it is a science-backed revolution changing how we understand metabolism, hunger, and sustainable fat…
GLP-1 Analogues Latest Market Analysis Report 2025
Global Info Research announces the release of the report "Global GLP-1 Analogues Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report provides a detailed overview of the GLP-1 Analogues market scenario, including a thorough analysis of the GLP-1 Analogues market size, sales quantity, average price, revenue, gross margin and market share.The GLP-1 Analogues report provides an in-depth analysis of the competitive landscape, manufacturer's profiles, regional and…
GLP-1 Market Taming Type 2 Diabetes and Obesity: The Therapeutic Promise of the …
GLP-1 Market Worth $95.4 Mn by 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds),
Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type…
In safe hands with the GLP checklist
The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks.
The values of transparency, traceability, assignment of responsibilities, and safekeeping are…
